Role of Montelukast in Asthma and Allergic Rhinitis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

August 28, 2018

Primary Completion Date

March 25, 2019

Study Completion Date

June 30, 2019

Conditions
Asthma and Allergic Rhinitis
Interventions
DRUG

Montelukast 10mg

Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening

Trial Locations (1)

Unknown

Dr. Faisal Faiyaz Zuberi, Karachi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Clinision

OTHER